HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Currently, resminostat, an HDAC inhibitor targeting HDAC class I, IIb and IV is tested in a phase II clinical trial in Europe and Japan as a maintenance therapy in advanced CTCL (RESMAIN, NCT02953301).